AstraZeneca to showcase clinical and scientific leadership in lung cancer at ELCC 2016

Click here to view online. Add this email to your safelist.

6 April 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will report new clinical trial and scientific data from their industry-leading lung cancer franchise of marketed and pipeline medicines at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland, 13 -16 April, 2016.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.